Evidence map›Paper›PMID 25671081›Full record

ArticleF1000Research2013

The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins.

Sandeep Chakraborty, Adela Rendón-Ramírez, Bjarni Ásgeirsson, Mouparna Dutta, Anindya S Ghosh, Masataka Oda, Ravindra Venkatramani, Basuthkar J Rao, Abhaya M Dandekar, Félix M Goñi

Open access · goldAbstract read
In one paragraph

Article in F1000Research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 5 countries.

Sandeep ChakrabortyDepartment of Biological Sciences, Tata Institute of Fundamental Research, Mumbai, 400 005, India ; Plant Sciences Department, University of California, Davis, CA, 95616, USA.
Adela Rendón-RamírezUnidad de Bio, Universidad del Pais Vasco, Bilbao, Spain.
Bjarni ÁsgeirssonScience Institute, Department of Biochemistry, University of Iceland, IS-107 Reykjavik, Iceland.
Mouparna DuttaDepartment of Biotechnology, Indian Institute of Technology Kharagpur, Kharagpur, 721302, India.
Anindya S GhoshDepartment of Biotechnology, Indian Institute of Technology Kharagpur, Kharagpur, 721302, India.
Masataka OdaDivision of Microbiology and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences, Niigata, 951-8514, Japan.
Ravindra VenkatramaniDepartment of Chemical Sciences, Tata Institute of Fundamental Research, Mumbai, 400 005, India.
Basuthkar J RaoDepartment of Biological Sciences, Tata Institute of Fundamental Research, Mumbai, 400 005, India.
Abhaya M DandekarPlant Sciences Department, University of California, Davis, CA, 95616, USA.
Félix M GoñiUnidad de Bio, Universidad del Pais Vasco, Bilbao, Spain.
Tata Institute of Fundamental Research · INIndian Institute of Technology Kharagpur · INUniversity of the Basque Country · ESNiigata University · JPUniversity of California, Davis · USUniversity of Iceland · IS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancreatitis. Previously, based on a computational analysis of the spatial and electrostatic properties of active site residues, we have demonstrated that phosphoinositide-specific phospholipase C (PI-PLC) from Bacillus cereus is a prolyl peptidase using in vivo experiments. In the current work, we first report the inhibition of the native activity of PI-PLC by two DPP4 inhibitors - vildagliptin (LAF-237) and K-579. While vildagliptin inhibited PI-PLC at micromolar concentrations, K-579 was a potent inhibitor even at nanomolar concentrations. Subsequently, we queried a comprehensive, non-redundant set of 5000 human proteins (50% similarity cutoff) with known structures using serine protease (SPASE) motifs derived from trypsin and DPP4. A pancreatic lipase and a gastric lipase are among the proteins that are identified as proteins having promiscuous SPASE scaffolds that could interact with DPP4 inhibitors. The presence of such scaffolds in human lipases is expected since they share the same catalytic mechanism with PI-PLC. However our methodology also detects other proteins, often with a completely different enzymatic mechanism, that have significantly congruent domains with the SPASE motifs. The reported elevated levels of serum lipase, although contested, could be rationalized by inhibition of lipases reported here. In an effort to further our understanding of the spatial and electrostatic basis of DPP4 inhibitors, we have also done a comprehensive analysis of all 76 known DPP4 structures liganded to inhibitors till date. Also, the methodology presented here can be easily adopted for other drugs, and provide the first line of filtering in the identification of pathways that might be inadvertently affected due to promiscuous scaffolds in proteins.

Indexed as

Bacillus cereusdiabeteslipasePI-PLCserine protease

Identifiers

PMID25671081
PMCPMC4309170
OpenAlexW1840343623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.